Agencies, 07 September: Russian research institute para tai khan laga Sputnik V vaccine data (vaccine’s safety aro efficacy) toh Indian authorities logode deshe. Etu khobor toh The Indian Express para jani powa hisaab te ase.
Senior officials koise, India para etu nemide Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology ke mangka thakise. Phase 1 aro 2 laga clinical trials te etu vaccine (Sputnik V) para gara immune jawab deya toh paise.
Ekta source para etiya tai khan toh v accine front te Russia logode engaged ase koise. Etu engagement toh yati Renu Swarup, Secretary, Department of Biotechnology para coordinate korise aro Russia te Indian Ambassador D B Venkatesh Varma para.
India te experts para etu “comprehensive data” te shaija te ekta option toh regulators para lakiya approvals powa bechide alak te Phase 3 clinical trial thakibo nemide ase koise. Official Sputnik website, sovereign wealth fund Russian Direct Investment Fund para jola hisaab te, Russia toh besi desh khan majode Saudi Arabia, UAE, Brazil aro Philippines be melikena Phase 3 clinical trials lobole plans ase.
Vaccine laga production toh September 2020 te suru hobole bhabona ase. Komti hoilebe 20 desh majode India be melikena Sputnik V pabole interest howa janaishe. Etu desh khan majode UAE, Saudi Arabia, Indonesia, the Philippines, Brazil, aro Mexico be ase.
Add Comment